Endonovo Therapeutics (OTCQB: ENDVD) today announced that the United States Patent and Trademark Office (“USPTO”) has issued a U.S. Patent for Application No. 15/549,748 covering method and apparatus for electromagnetic treatment of multiple sclerosis (“MS”). “This issuance follows our prior patents related to the methods of treating post-operative pain and edema,” Endonovo’s Chief Medical Officer and Harvard trained Physical Medicine and Rehabilitation specialist Dr. Nev Zubcevik said in the news release. “The SofPulse(R) technology is research proven and universally applicable to inflammatory conditions. Our preliminary research in the field of Autoimmune Encephalomyelitis – the inflammatory autoimmune model of multiple sclerosis, reveals significant change in the EAE score of treated animals when compared to sham. We are looking forward to expanding our technology applications into neuroinflammatory disorders; we believe our growing patent portfolio reinforces Endonovo’s leadership position in utilizing SofPulse(R) to address pain while also underscoring the pioneering nature of the company’s Pulsed Electromagnetic Field-based (PEMF) Electroceuticals(R).”
To view the full press release, visit http://ibn.fm/fKY6a
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals(R) therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (“CNS”) Disorders, including traumatic brain injury (“TBI”), acute concussions, post- concussion syndrome and multiple sclerosis. The Company’s non-invasive Electroceutical(R) therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals(R) therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDVD are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php